171 related articles for article (PubMed ID: 27412626)
21. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees.
Kowada A
Am J Infect Control; 2011 Dec; 39(10):e67-72. PubMed ID: 21839543
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.
Swaminath A; Bhadelia N; Wang YC
Inflamm Bowel Dis; 2013 Oct; 19(11):2444-9. PubMed ID: 23945184
[TBL] [Abstract][Full Text] [Related]
23. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.
Auguste P; Tsertsvadze A; Pink J; Court R; McCarthy N; Sutcliffe P; Clarke A
BMC Infect Dis; 2017 Mar; 17(1):200. PubMed ID: 28274215
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy.
Kowada A
Mol Diagn Ther; 2010 Dec; 14(6):367-73. PubMed ID: 21275454
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations.
Kowada A; Deshpande GA; Takahashi O; Shimbo T; Fukui T
Mol Diagn Ther; 2010 Aug; 14(4):229-36. PubMed ID: 20799765
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers.
del Campo MT; Fouad H; Solís-Bravo MM; Sánchez-Uriz MA; Mahíllo-Fernández I; Esteban J
Infect Control Hosp Epidemiol; 2012 Dec; 33(12):1226-34. PubMed ID: 23143360
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country.
Lin WC; Lin HH; Lee SS; Sy CL; Wu KS; Chen JK; Tsai HC; Chen YS
J Microbiol Immunol Infect; 2016 Oct; 49(5):729-736. PubMed ID: 25442858
[TBL] [Abstract][Full Text] [Related]
28. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain.
Calzada-Hernández J; Anton J; Martín de Carpi J; López-Montesinos B; Calvo I; Donat E; Núñez E; Blasco Alonso J; Mellado MJ; Baquero-Artigao F; Leis R; Vegas-Álvarez AM; Medrano San Ildefonso M; Pinedo-Gago MDC; Eizaguirre FJ; Tagarro A; Camacho-Lovillo M; Pérez-Gorricho B; Gavilán-Martín C; Guillén S; Sevilla-Pérez B; Peña-Quintana L; Mesa-Del-Castillo P; Fortuny C; Tebruegge M; Noguera-Julian A
Eur J Pediatr; 2023 Jan; 182(1):307-317. PubMed ID: 36335186
[TBL] [Abstract][Full Text] [Related]
29. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients.
Triverio PA; Bridevaux PO; Roux-Lombard P; Niksic L; Rochat T; Martin PY; Saudan P; Janssens JP
Nephrol Dial Transplant; 2009 Jun; 24(6):1952-6. PubMed ID: 19164327
[TBL] [Abstract][Full Text] [Related]
30. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA.
Nijhawan AE; Iroh PA; Brown LS; Winetsky D; Porsa E
BMC Infect Dis; 2016 Oct; 16(1):564. PubMed ID: 27733123
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.
de Perio MA; Tsevat J; Roselle GA; Kralovic SM; Eckman MH
Arch Intern Med; 2009 Jan; 169(2):179-87. PubMed ID: 19171815
[TBL] [Abstract][Full Text] [Related]
33. Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results.
Gran G; Aßmus J; Dyrhol-Riise AM
BMC Public Health; 2013 Apr; 13():353. PubMed ID: 23590619
[TBL] [Abstract][Full Text] [Related]
34. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.
O'Shea MK; Fletcher TE; Beeching NJ; Dedicoat M; Spence D; McShane H; Cunningham AF; Wilson D
PLoS One; 2014; 9(5):e97366. PubMed ID: 24816576
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.
Deuffic-Burban S; Atsou K; Viget N; Melliez H; Bouvet E; Yazdanpanah Y
Int J Tuberc Lung Dis; 2010 Apr; 14(4):471-81. PubMed ID: 20202306
[TBL] [Abstract][Full Text] [Related]
36. Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection.
De Keyser E; De Keyser F; De Baets F
Acta Clin Belg; 2014 Oct; 69(5):358-66. PubMed ID: 25018132
[TBL] [Abstract][Full Text] [Related]
37. Discordance between TST and QFT-TBGold Plus for Latent Tuberculosis Screening among Under-Five Children: An Interim Analysis.
Surve S; Bhor V; Naukariya K; Begum S; Munne K; Tipre P; Sutar N; Jaiswal A; Bhonde G; Chauhan S; Shah I
J Trop Pediatr; 2021 Dec; 67(6):. PubMed ID: 34904674
[TBL] [Abstract][Full Text] [Related]
38. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area.
Li J; Yip BHK; Leung C; Chung W; Kwok KO; Chan EYY; Yeoh E; Chung P
PLoS One; 2018; 13(1):e0189531. PubMed ID: 29293514
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.
Hardy AB; Varma R; Collyns T; Moffitt SJ; Mullarkey C; Watson JP
Thorax; 2010 Feb; 65(2):178-80. PubMed ID: 19996345
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis.
Diel R; Wrighton-Smith P; Zellweger JP
Eur Respir J; 2007 Aug; 30(2):321-32. PubMed ID: 17504793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
